Investigational alpha-MSH-derived anti-inflammatory tripeptide
KPV
aka Lys-Pro-Val · L-lysyl-L-prolyl-L-valine · alpha-MSH(11–13)
Goals: Recovery & injury · Skin & hair Compare with another peptide →
User reports
approximate — combined from two independent Reddit reads
Men 45–60
0 men aged 45–60
No reports in this group yet.
All men
0 men
No reports in this group yet.
Everyone
32 people
- Positive: 11 of 32 (34%)
- Mixed: 11 of 32 (34%)
- Negative: 5 of 32 (16%)
- No effect: 2 of 32 (6%)
- Unclear: 3 of 32 (9%)
| Item | Reports |
|---|---|
| Inflammation | 11 of 32 (34%) |
| Gut | 6 of 32 (19%) |
| Energy | 3 of 32 (9%) |
| Joints / tendons | 3 of 32 (9%) |
| Skin | 3 of 32 (9%) |
| Sleep | 3 of 32 (9%) |
| Recovery | 2 of 32 (6%) |
| Focus / cognition | 1 of 32 (3%) |
| Item | Reports |
|---|---|
| Other | 6 of 32 (19%) |
| GI upset | 5 of 32 (16%) |
| Fatigue | 2 of 32 (6%) |
| Headache | 1 of 32 (3%) |
| Low mood | 1 of 32 (3%) |
| Water retention | 1 of 32 (3%) |
| Item | Reports |
|---|---|
| Side effects | 3 of 32 (9%) |
User reports are anecdata, not evidence: self-selected, unverified, often combined with other compounds.
In their words
“I believe it helped.”
“I was able to tolerate KPV shockingly, but noticed no benefits.”
“my bowels feel a lot sorer than usual and increased BM's”
“noticed no difference from any of them on gut symptoms”
“I personally tried KPV subcutaneously. 200µg for 12 days (one 5mg vial). I didn't find anything better. Significant improvements on the Bistrol scale.”
“I've been using it for over 4 weeks now and my inflammation has literally disappeared. My knees feel so much better”
“Same KPV made me so constipated I stopped for a few days”
“It calms my MCAS for an hour, then makes it worse until the next dose. And since repeated use gives me mood swings”
Read summaries and method notes
Read 1. No man aged 45–60 and no explicitly male reporter. Five users: one believed injectable KPV helped, two noticed no gut benefit, one had a Crohn's flare/sorer bowels starting oral KPV (unsure it was the cause), one reported gut repair from a multi-ingredient product with KPV, BPC-157 and larazotide.
Read 2. No stated age or sex at all. Thirty users from 9 threads, mostly MCAS, SIBO, long-COVID and Crohn's communities: 11 positive, 10 mixed, 5 negative, 1 no effect, 3 unclear. Benefits: inflammation often reduced within minutes to days (11), gut and stool quality (6), joints and skin (3 each), sleep and energy (3 each). Side effects: constipation or bad bloating (5), initial MCAS flares, swelling and rebound worsening (6), exhaustion (2); three stopped. Symptoms often returned straight after stopping — symptomatic rather than curative. Nearly half (14) stacked, e.g. KLOW blends or tirzepatide.
Note 1. Sex and age generally absent. One positive gut-repair report used a mixed product and is treated as stacked. The Crohn's user questioned whether KPV caused the worsening, so the verdict is mixed.
Note 2. No age/sex data. Third-party reports (a brother, an 'RS') were excluded. Nearly half combined KPV with KLOW/GHK-Cu, BPC-157 or tirzepatide; a product-guide subreddit was excluded.
Each read counted people independently. Overlap between the two reads is estimated from shared threads and removed; counts are approximate. How we count.
Summary
C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone. Sequence: Lys-Pro-Val (K-P-V). MW: ~341 Da.
Proposed mechanism
In cell and mouse models KPV affected inflammatory signaling, including NF-κB and cytokines; these are not established clinical mechanisms or proof of human oral exposure.
- PepT1 uptake: Transport and reduced inflammatory signaling were observed in cultured cells and mouse colitis models. (study)
- Receptor dependence: Some experimental effects persisted in mice with nonfunctional MC1R, but receptor independence is not universal; keratinocyte responses varied with experimental conditions. (colitis; keratinocytes)
- IL-1β homology: The prior loop-exposure explanation concerned KdPT, a different tripeptide, and is not an established KPV mechanism. (study)
Antimicrobial activity: Cutuli and colleagues reported laboratory antimicrobial and neutrophil effects; these do not establish clinical superiority or preserved infection defense in patients. (study)
Safety
- Human safety, pharmacokinetics and safe dose ranges remain unknown.
- No identified adverse-event reports do not establish safety.
- Immunogenicity, aggregation and ingredient quality are unresolved.
- Long-term, reproductive, carcinogenic and interaction safety are insufficiently characterized.
From labels, regulators and trials. No signal in small studies ≠ safe.
Legal status
US FDANot approved
Not approved; favorable July PCAC recommendation; October HHS draft/interim policy. July 23, 2026 PCAC favored free-base and acetate inclusion, contrary to staff. Category 2 removal: April 22. October HHS text specifies KPV acetate oral/topical forms under conditions, not SC injections. Federal Register calls policy draft; final replacement or final 503A rule not found. Source
checked 2026-11-13WADA 2026Likely prohibited (S0)
Not listed by name; S0 prohibition applies to unapproved pharmacological substances (application to KPV is an inference). Source
checked 2026-11-13EU
FDA's 2026 review found no EMA-authorized KPV free-base or acetate product; current authorization not found in this refresh. Source
checked 2026-11-13Re-check pending: HHS interim policy is a draft; re-check after the comment period.
Evidence D gut and skin anti-inflammatory use
D stands. Cell and mouse colitis data only; FDA's 2026 review found no administered-human study.
Human trials · 0
No human trials found for the marketed use.
Dose ranges
Reported ranges from labels and studies, with context. Not a recommendation.
No data.
Editorial ratings EDITORIAL
Editors’ judgement, 0–5. Opinion, not data; separate from grade and user score.
Sources
- hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
- wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
- fda.gov/media/193346/download
- fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-pres
- govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm
- fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-c
- ema.europa.eu/en/medicines
- pubmed.ncbi.nlm.nih.gov/18061177/
- pubmed.ncbi.nlm.nih.gov/18092346/
- pubmed.ncbi.nlm.nih.gov/12750433/
- pubmed.ncbi.nlm.nih.gov/15102092/
- pubmed.ncbi.nlm.nih.gov/10670585/
- pmc.ncbi.nlm.nih.gov/articles/PMC2431115/
- pmc.ncbi.nlm.nih.gov/articles/PMC3157275/
Reddit threads read · 11
- r/Peptides
- r/Biohackers
- r/Longcovidgutdysbiosis
- r/SIBO
- r/ScienceBioTechnology
- r/PeptidePathways
- r/NTNPerformance
- r/MCAS
- r/MCAS
- r/covidlonghaulers
- r/MCAS
Research checked 2026-11-13.